A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unresectable squamous cell carcinoma.

Trial Profile

A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unresectable squamous cell carcinoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Acronyms Accrobat
  • Most Recent Events

    • 07 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top